For citations:
Rudakova A.V., Gusev D.A., Uskov A.N., Konovalova L.N., Lobzin Yu.V. PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION. Journal Infectology. 2017;9(1):100-103. (In Russ.) https://doi.org/10.22625/2072-6732-2017-9-1-100-103
.png)
.png)
Email this article 